

Diagnostica Vertrieb GmbH, Oehleckerring 11-13

22419 Hamburg, Germany

**Telephone:** +49 (0)89 3799666-6 | **Fax:** +49 (0)89 3799666-99

E-Mail: info@biozol.de

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

## **Product Datasheet**

## Goat Antiserum anti-Horse IgG (F(ab)2)-unconj., MinX none DNA-SEC-182437

Article Name	Goat Antiserum anti-Horse IgG (F(ab)2)-unconj., MinX none
Biozol Catalog Number	DNA-SEC-182437
Supplier Catalog Number	SEC-182437
Alternative Catalog Number	DNA-SEC-182437
Manufacturer	dianova
Host	Goat
Category	Antikörper
Application	ELISA,IHC,WB
Species Reactivity	Equine
Immunogen	Horse IgG F(ab)2 fragment
Conjugation	Unconjugated
Format	Antiserum
Target Specificity	IgG (F(ab')2)
Cross-Adsorption (MinX)	no cross-adsorbtion
Product Description	Anti-Horse IgG F(ab)2 Antibody generated in goat is a proteolytic fragment of immunoglobulin G (IgG) obtained by limited digestion with the enzyme pepsin under controlled conditions of temperature, time and pH. F(ab)2 molecules lack the Fc portion of
Clonality	Polyclonal

Concentration	90 mg/mL
Isotype	Ig
Buffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Purity	This product was prepared from monospecific antiserum by a delipidation and defibrination. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-goat serum, Horse IgG, Horse IgG F(ab')2 and Horse Serum. No reaction was observed against Horse IgG F(c).
Form	Lyophilized
Formula	20 mM K3PO4,150 mM NaCl,pH 7,2,lyophilisate,Azide/BSA free
Target	Horse
Antibody Type	Secondary Antibody
Application Dilute	ELISA Dilution: 1:20,000 - 1:100,000, Immunohistochemistry Dilution: 1:1,000 - 1:5,000, Western Blot Dilution: 1:2,000 - 1:10,000
Application Notes	This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.